few significant in the with programs new progress immunology and inception, Thank and billion products, XXXX. Imbruvica R&D $XX organization contributed of Venclexta, which and We've in Since revenue with collectively impressive past in late-stage Rinvoq our our with Skyrizi. particularly clearly you, oncology our made set has years, approximately an Rick. hematologic pipeline over delivered in
to We also see expected clinical continue over to the studies and of registrational programs early late-stage many our mid-stage next years. with transition several to significant assets evolution
approved overview immunology innovative to the the will event, second drive investor data across our in in to-date Rinvoq. decade. induction dupilumab AbbVie robust We pipeline At late-stage dermatitis. provided generated we in Skyrizi for new Results that colitis studies X from a we of growth head-to-head two detailed our and our of the and atopic ulcerative for Phase study half the indications. assets programs, and replenish December, pipeline results first recent data in for to Included from presented the the immunology continue from with in additional study topline versus Rinvoq positive event highlighting potential this have
study anticipated maintenance study half from of XXXX. results this the the in UC X in with second regulatory Phase to the expect the later quarter, We submissions and induction second year see UC from middle of this
results US and a in arthritis of we address a of in to and decisions currently applied first expect such US expect the Rinvoq second psoriatic the recently no from quarter the safety and in for priority half applications the year. and based to there Commission to as Rinvoq. for following European the I spondylitis are in the the want malignancies indications We outcomes tofacitinib's At study approval MACE from an inhibitor specifically their approval regulatory to present, approval review Our in year. ankylosing take in are review data of in post-marketing safety, topic second the half atopic suggest Europe for in and JAKX received specific the those study. on decision Rinvoq this dermatitis safety moment under
baseline relative signal an malignancies Rinvoq or We updated up MACE the trials our expected to than with present. MACE at any with including not clinical rates. other Xeljanz. elevated of JAK competitors aware are any malignancies time analysis it We not or been a risk have of and across of regulatory Rates for pooled periodically conducted elevated have the Rinvoq DVT, inhibitor to database submission or and the to Rinvoq's for
no there rates those change in over increase Importantly, time. meaningful has been or
a At considered we remain events have the experience. If events, that MACE approved followed we rates our is RA, risk than which highest for and evidence. X,XXX of Additionally, more across in totaling our standard MACE more is population RA, treated patients for low. than in adjudicate look DVT, database long-term the increased dose at we X,XXX patient-years'
which patient-years, for XXX favorably per X.X to XXX is expected events patient-years. compares MACE of to X.X of events the X.X rate Our rate
of skin rates is per malignancy, addition, to range In X.X rate XX there no we consistent events of Similarly, similar follow-up dose-response excluding XX between also the patient-years. again, of with X.XX and evidence cancer no patient-years. evidence and with between rate the non-melanoma see This perXXX is of And XX-milligrams. of XX-milligram is X.XX XXX a the expected doses. dose-response a
an the Moving seen from X and week for arthritis. Skyrizi; become date, compared important induction results studies, we moderate the severe Based two option potential to improvement Crohn's now on endoscopic to symptom Crohn's psoriatic with disease in Skyrizi with clinical has for the placebo significant disease. generated remission endpoints the we demonstrated In to patients early top-line treatment Skyrizi improvements new programs Skyrizi as in reported Crohn's also believe data recently to and four. Phase to as
skin skin with the psoriatic from significant in regulatory joint maintenance in We results study XXXX. this Skyrizi's and results compared We expect we of activity Phase submissions improvements very in endpoints patients with We're impressive second that believe disease a hallmark both disease the in as arthritis skin readouts it the applications making year. year studies in arthritis, first progress we We're compelling in joint in make several the where and data offering a involvement. with our XXXX. for Skyrizi submit this mixed programs regulatory is our We activity disease we also Crohn's X have anticipated with phase good to for see expect transitions half the mid-stage where placebo. to and the immunology early well in joint plan across to clearance on of psoriatic saw of program the seen and and Skyrizi half later that pleased
rheumatica. studies colitis, conjugate Phase expect T Phase second our and expected begin data And these X new in readouts programs year. in in X for for oral second inhibitor We our we we'll ABBV-XXX, CDXX in X COVID-related in three Xb with TNF of this Phase to as year. pipeline milestones and delays well for Both results now Phase of our antagonist dose-ranging data progress experienced to studies for RA ROR-gamma advancing see ulcerative our as for the including ABBV-XXX, significant in disease psoriasis. quarter steroid polymyalgia Crohn's study continue quarter ravagalimab, a In regulatory both oncology, last and slight the for with numerous make proof-of-concept
As we their the addition achieved plus different following assets. eight meeting stopping therapy one-year lemzoparlimab. including epcoritamab efforts, maintain Imbruvica included nearly assets who data frontline programs data remission new from through rate the in-licensing at undetectable Notable abstracts where after of well Phase showed CDXxCDXX as Venclexta We recent new ASH several in CLL, with showcased brought at XX% of from in MRD anti-CDXX several free and XX presentations the Genmab's I-Mab's from presented which disease survival. combination CAPTIVATE patients deep the a this mark trial evaluating X our
to The therapy become delivered also from collaboration studies showed the published Murano no activity in patients lemzoparlimab in program Venclexta neurotoxicity. our results, Phase in of the and combinations every initial from updates began helping data in months presented B-cell a we CDXxCDXX is provide lymphoma group, to a with encouraging epcoritamab from myeloma as trial months These patients to and this multiple in these the were The despite being across Venclexta of relapsed-refractory progression-free reported in from tested once results Phase will limited relapsed Updated on bispecific And setting or a or These in Murano tolerated trial new therapy. years to compared results antibody XX% patients a results We evaluating lemzoparlimab activity safety overall X the three-week in events has subcutaneously of bispecific an Venclexta's begin Epcoritamab X potential with CRS epcoritamab a multiple lymphoma. and a large rates has demonstrating were in TNB-XXXB at today. achieving In its agent progression-free Genmab. a relapsed-refractory bispecific diffuse XX TeneoBio. received TNB-XXXB We With lemzoparlimab MDS. partner the survival sustained in presented development study, as in promising new as encouraging X well fixed B-cell five-year survival. number its in and or response large refractory pretreated or recently agent Phase was off-target study multiple option of Phase having AML promising anti-tumor few patients of convenience epcoritamab being for good serious X a latest dose-escalation number data very well become CRS bendamustine-rituximab group, showing profile with patients. Grade demonstrated doses and also better XX study all B-cell observed. DLBCL immunotherapy a partial prior follicular hematological plan profile rituximab collaboration benefits the relapsed-refractory in lines targeting TNB-XXXB duration demonstrated three adverse study and I-Mab achieve ASH. after developed Initial we MDS Phase novel a myeloma. no of X with with for the epcoritamab a X with Grade best-in-class response malignancies demonstrated efficacy including AML tolerated X of favorable heavily consistent Based AML, Phase CLL initial abstract potential X engaging treatment no on single events toxicities this is was higher a and well higher evaluating a BCMA/CDX myeloma. and that T-cell treatment. believe and dosing, median safety evaluating developed year presented progresses. also stopping BCMA and malignancies results and results at the more the with CDX from provided
roughly We patients. the cell saw X of lung an Phase heavily response high With study pretreated patients was of from objective also Teliso-V EGFR with X Based and met highly intermediate cancer response this in criteria role there the non-squamous, population, The expressed includes results patients represents c-MET. which encouraging demonstrating both believe which this study the evaluating program. recently an for interim non-small wild-type the In analysis Teliso-V lung cancer for Stage from a in data non-squamous, with rate target over-expressed XX%. population. non-small a cell objective Teliso-V XX% these wild-type advancing with on that rate is results, XX% important we in c-MET, expression, of EGFR
of planning We of regarding opening an this regulators the will filing. the be study study are second and stage discussions accelerated with to the support potential
with We expect another Phase XXXX see Imbruvica across data regulatory year, readouts well with submissions second all important be Imbruvica the as year This the the stages development. frontline MCL MCL in SHINE for several expect CLL for half for in X and the oncology submissions as frontline with pipeline our year. data to of the expected year. second CLL for submission in study with regulatory line to of or frontline we in half second of regulatory expected [ph] combination greater in Venclexta in Data
we early-stage data navitoclax studies programs relapsed-refractory We see and for our in myelofibrosis. numerous to also registration in in expect Venclexta And pipeline. see expect high-risk oncology from data enabling MDS from to
the under also well. are progressing with collaboration addition, Calico programs In
includes more preclinical which programs Our discovery than partnered or of effort strong development. is pipeline a XX comprised in targets, novel active of
bio-available the Calico discovery and represents applicability inhibitors, broad potential a PTPNX on immuno-oncology clinical two have currently currently variety have focused in oncology with of in class proof-of-concept which and a The of X to significant is which program this we neuroscience activation into eIFXB from areas highly Inhibition cancer neurodegeneration. data in such The has a advanced which breakthrough XXXX. in program targets seen ABBV-CLS-XXX development types. function this in the clinic Calico the two Phase an neurodegenerative and disease lead we assets this and ALS been in prevent at evidence and pathway lead considered key potential restore in conserved We've historically programs, pathology in target of immunity regulator expect orally The in see act the to that multiple steps integrated of inhibitors We traumatic development has XXX. stress and response activator, program Importantly, injury. cycle well brain in a pathway. immune number Parkinson's of un-druggable. have as novel and PTPNX of as is tumor a diseases pathway as have
and eIFXB to study plan lead prevention ABBV-CLS-XXXX we last activator through we later our program for regulatory currently other begin X Our we in FDA. this registrational in and submitted Phase progressing atogepant with episodic the ALS. patients our year, application to year recently is In updates, migraine a completed neuroscience
episodic in second depressive in has offer We including submissions in major and The believe late-stage expect the XXXX, from programs that X an and end as Parkinson's approval migraine. several for the from studies disease for see benefit-risk generated expected disorder treatment patients XXX prevention ABBV-XXX Vraylar our atogepant half year. support to from we profile to quarter. results decision neuroscience advanced the regulatory the results strong of benefits oral pivotal by data the a for Phase potential In the Phase two with expect third safe, assets, for of X effective, program to in meaningful a option of the data we
data to Elezanumab expect and proof-of-concept antibody Phase our Phase study in see sclerosis ABBV-XEXX, in multiple X disease. a also in lead Alzheimer's study in a anti-tau We for X
in In tau toxins include development, Alzheimer's, CDXX, at addition approaches other have programs as preclinical clinical a XEXX, aimed make well tau regulatory to and as and in to neuroinflammation These Aesthetics, of portfolio as to year. different we TREMX development. number approaches specificity approaches progress antibodies submissions, in and we our currently fillers promising with data including expected continue starts tau. as this pivotal several readouts intracellular with In excellent with well our epitope dermal study of clear facial
formulations innovative new short-acting as include indications programs liquid Our and toxins. the for well as such Botox long and toxins as both new
our for on registration have such HArmonyCa, Juvederm fillers the year. develop application novel the also positive enabling And treatment with studies in later based dermal X regulatory submit quarter Phase be the from this Collection as AGN-XXXXXX plan fourth to associated We We decision results programs well entering as expect the evaluating eye our month an which to eye in new of presbyopia. will and as for U.S. of studies drop indications the in symptoms topical care, this approval the
Rob? indication approvals, and turn pivotal study XXXX over to R&D remained major our we includes high guidance. XX XXXX quarter continued all stages advancement and a our summary, dozen maintain of to expect XX from that, on COVID-related minimize programs. more continuity new We're we success regulatory multiple This performance our in for more despite than readouts five significant our and additional fourth early data readouts, year. With were comments Rob and steady delays. program I'll last able mid-stage well-positioned So across pipeline, and productivity submissions, challenges than call again for the this asset or entering year and half
